Japan Drug Firm Bets $3 Billion On Castoffs And Hype
September 09, 2019 at 22:05 PM EDT
The lucrative deal with Sumitomo is just the treatment Roivant needs to keep its model ticking. But it’s unlikely to fix what ails its Japanese partner.
